文献速递心脏核医学

正电子发射断层显像与单光子发射计算机断层显像心肌灌注显像对心脏代谢疾病患者风险预测的比较有效性

Comparative effectiveness of positron emission tomography and single-photon emission computed tomography myocardial perfusion imaging for predicting risk in patients with cardiometabolic disease.
PubMed 文献 · J Nucl Cardiol · 2024-07-10

本研究回顾性随访2006至2020年因心脏代谢疾病(肥胖、糖尿病或慢性肾脏病)且无已知冠心病而转诊行PET、运动SPECT或药物SPECT心肌灌注显像的21544例患者,经倾向性匹配比较主要不良心血管事件发生率与风险。中位随访6.4年,正常PET识别低风险(0.9%/年MACE)患者,异常PET识别高风险(4.2%/年MACE)患者;正常药物SPECT仍为中风险(1.6%/年,与正常PET相比P<0.001)。与药物SPECT相比,PET联合心肌血流储备可检测非阻塞性冠心病包括冠状动脉微血管功能障碍,并更准确区分低风险与较高风险个体。

要点

  • 心脏代谢疾病在MPI转诊患者中常见(PET 67%、SPECT 55%),且PET组更高(P<0.001)。
  • 阻塞性CAD表现(TPD>5%)不常见(PET 21%、SPECT 11%),而PET心肌血流储备受损(<2.0)常见(62%)。
  • 正常PET为低风险(0.9%/年MACE),异常PET为高风险(4.2%/年MACE),正常药物SPECT仍为中风险(1.6%/年)。

核心结论

  • 心脏代谢疾病在MPI转诊患者中常见,并与异质性风险水平相关。
  • 与药物SPECT相比,PET联合心肌血流储备可检测非阻塞性冠心病包括冠状动脉微血管功能障碍,并更准确区分低风险与较高风险个体。

研究设计与样本

  • 回顾性随访2006至2020年转诊行PET、运动SPECT或药物SPECT心肌灌注显像的心脏代谢疾病(肥胖、糖尿病或慢性肾脏病)且无已知冠心病患者,共21544例。
  • 采用泊松回归和Cox回归,在倾向性匹配的PET与SPECT患者中比较复合主要不良心血管事件(年化心源性死亡或急性心肌梗死)的发生率与风险。

主要发现

  • 心脏代谢疾病在PET组2308例(67%)和SPECT组9984例(55%)中高度流行,PET转诊者中更高(P<0.001)。
  • 阻塞性CAD表现(TPD>5%)不常见(PET 21%、SPECT 11%);PET心肌血流储备受损(<2.0)常见(62%)。
  • 中位随访6.4年的倾向性匹配分析中,正常PET识别低风险(0.9%/年MACE)患者,异常PET识别高风险(4.2%/年MACE)患者。
  • 正常药物SPECT患者仍为中风险(1.6%/年,与正常PET相比P<0.001)。

关键数值与推荐

  • 正常SPECT定义为总灌注缺损(TPD)<5%,反映无阻塞性CAD。
  • 正常PET定义为TPD<5%且心肌血流储备≥2.0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The epidemiology of coronary artery disease (CAD) has shifted, with increasing prevalence of cardiometabolic disease and decreasing findings of obstructive CAD on myocardial perfusion imaging (MPI). Coronary microvascular dysfunction (CMD), defined as impaired myocardial flow reserve (MFR) by positron emission tomography (PET), has emerged as a key mediator of risk. We aimed to assess whether PET MFR provides additive value for risk stratification of cardiometabolic disease patients compared with single-photon emission computed tomography (SPECT) MPI. METHODS: We retrospectively followed patients referred for PET, exercise SPECT, or pharmacologic SPECT MPI with cardiometabolic disease (obesity, diabetes, or chronic kidney disease) and without known CAD. We compared rates and hazards of composite major adverse cardiovascular events (MACEs) (annualized cardiac mortality or acute myocardial infarction) among propensity-matched PET and SPECT patients using Poisson and Cox regression. Normal SPECT was defined as a total perfusion deficit (TPD) of <5%, reflecting the absence of obstructive CAD. Normal PET was defined as a TPD of <5% plus an MFR of ≥2.0. RESULTS: Among 21,544 patients referred from 2006 to 2020, cardiometabolic disease was highly prevalent (PET: 2308 [67%], SPECT: 9984 [55%]) and higher among patients referred to PET (P < 0.001). Obstructive CAD findings (TPD > 5%) were uncommon (PET: 21% and SPECT: 11%). Conversely, impaired MFR on PET (<2.0) was common (62%). In a propensity-matched analysis over a median 6.4-year follow-up, normal PET identified low-risk (0.9%/year MACE) patients, and abnormal PET identified high-risk (4.2%/year MACE) patients with cardiometabolic disease; conversely, those with normal pharmacologic SPECT remained moderate-risk (1.6%/year, P < 0.001 compared to normal PET). CONCLUSIONS: Cardiometabolic disease is common among patients referred for MPI and is associated with a heterogenous level of risk. Compared with pharmacologic SPECT, PET with MFR can detect nonobstructive CAD including CMD and can more accurately discriminate low-risk from higher-risk individuals.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Huck DM, Divakaran S, Weber B, et al. Comparative effectiveness of positron emission tomography and single-photon emission computed tomography myocardial perfusion imaging for predicting risk in patients with cardiometabolic disease. J Nucl Cardiol. 2024. PMID: 38996910. doi:10.1016/j.nuclcard.2024.101908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。